Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Current Assets (2018 - 2026)

Immunovant filings provide 8 years of Current Assets readings, the most recent being $1.0 billion for Q4 2025.

  • Quarterly Current Assets rose 152.81% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 152.81% year-over-year, with the annual reading at $767.8 million for FY2025, 15.32% up from the prior year.
  • Current Assets hit $1.0 billion in Q4 2025 for Immunovant, up from $573.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.0 billion in Q4 2025 and bottomed at $291.2 million in Q3 2023.
  • Average Current Assets over 5 years is $535.7 million, with a median of $510.2 million recorded in 2022.
  • The largest annual shift saw Current Assets soared 274.97% in 2021 before it crashed 41.96% in 2024.
  • Immunovant's Current Assets stood at $540.5 million in 2021, then dropped by 15.92% to $454.4 million in 2022, then soared by 56.41% to $710.8 million in 2023, then crashed by 41.96% to $412.5 million in 2024, then surged by 152.81% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Current Assets are $1.0 billion (Q4 2025), $573.5 million (Q3 2025), and $651.8 million (Q2 2025).